UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13
AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number1-09499
GlaxoSmithKline Services Unlimited (formerly Glaxo Wellcome plc)
(Exact name of registrant as specified in its charter)
980 Great West Road
Brentford, Middlesex TW8 9GS
England
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i)  | Rule 12h-3(b)(1)(i) | |
| Rule 12g-4(a)(1)(ii) | Rule 12h-3(b)(1)(ii) | |
Rule 12g-4(a)(2)(i)  | Rule 12h-3(b)(2)(i) | |
| Rule 12g-4(a)(2)(ii) | Rule 12h-3(b)(2)(ii) | |
| Rule 15d-6 |
Approximate number of holders of record as of the certification or notice date:Two
Pursuant to the requirements of the Securities Exchange Act of 1934 GlaxoSmithKline Services Unlimited (formerly Glaxo Wellcome plc) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
| Date: 21 April 2005 | By: /s/ Richard Stephens | |
| Assistant Company Secretary |